Arianna Paris

Arianna Paris

Auto-generated profile, based on publicly available information

Arianna Paris

Department of Ophthalmology, Institute of Clinical Neurosciences of Southern Switzerland (INSI), Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2024 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
APArianna Paris
Arianna Paris
GVGiulio Volpe
Giulio Volpe
KPKathrin Perruchoud-Ader
Kathrin Perruchoud-Ader
ACAlex Casanova
Alex Casanova
MMMoreno Menghini
Moreno Menghini
GGGabriela Grimaldi
Gabriela Grimaldi
Background/aims Intravitreal injection (IVT) of anti-vascular endothelial growth factor agents is the standard of care for several retinal diseases but can cause intraocular pressure (IOP) elevations. This study investigates short-term postinjection IOP changes following aflibercept 8 mg and faricimab, compared with aflibercept 2 mg. Methods This observational, prospective study included 90 patients with age-related macular degeneration or diabetic macular oedema, divided into three groups, receiving aflibercept 2 mg, aflibercept 8 mg or faricimab. IOP was measured using an iCare IC200-tonometer preinjection (T0) and at 30 s (T1), 5 min (T2) and 15 min (T3) postinjection. Primary outcomes included IOP changes at the four time points within and between treatment groups. The incidence of transient visual loss requiring paracentesis was recorded. Results All groups experienced a significant IOP increase at T1, with mean IOP increase being 41.47±12.95 mm Hg for aflibercept 2 mg, 43.46±8.97 mm Hg for aflibercept 8 mg and 32.19±11.06 mm Hg for faricimab. By T2, IOP differences were not significant, and by T3, mean IOP returned within normal limits across all groups. Faricimab showed a smaller initial IOP spike than both aflibercept formulations, but this difference was not statistically significant at T2 and T3. Conclusion Transient IOP spikes are observed post-IVT of aflibercept 8 mg and faricimab, with similar trends to aflibercept 2 mg. The initial IOP elevation normalised within 15 min. Faricimab had a lower initial spike, but overall IOP profiles were comparable across different agents.

25 March 2025 in Ophthalmology Retina
Verified
Journal Article
Open access
GGGabriela Grimaldi
Gabriela Grimaldi
AAAude Ambresin
Aude Ambresin
IPIsabel B. Pfister
Isabel B. Pfister
CGChristin Gerhardt
Christin Gerhardt
CPChristina Plasencia
Christina Plasencia
JGJustus G. Garweg
Justus G. Garweg
To report the efficacy and safety of switching to faricimab in a real-world, Swiss cohort of patients with pre-treated neovascular age-related macular degeneration (nAMD). Retrospective, multicenter, longitudinal observational study conducted at 11 centers of the Swiss Retina Research Network. We included 353 eyes of 325 patients who were switched to intravitreal faricimab after prior anti-vascular endothelial growth factor (anti-VEGF) therapy and followed for a minimum of 12 months between May 1, 2022 and October 30, 2024. Demographic characteristics, baseline functional and optical coherence tomography findings, treatment history, and outcomes at 12 months post-switch to faricimab were extracted from the patients' electronic case report forms. Change in best-corrected visual acuity (BCVA), central subfield thickness (CST), presence of retinal fluid (RF) and pigment epithelial detachment, treatment intervals and safety signals. Twelve months after switch, mean BCVA remained unchanged while mean CST decreased from 315.3 μm to 263.9 μm (p<0.01). Fast drying (absence of RF) after 1 faricimab injection was observed in 134 eyes (38%) and correlated positively with the treatment interval at 12 months (r(301)=0.24, p<0.01). After 12 months,169 (47.9%) eyes demonstrated absence of retinal fluid compared to 10.2% at switch. Mean treatment interval increased from 5.8 ± 2.5 weeks at switch to 8.3 ± 4.2 weeks at 12 months, whereas extended treatment intervals (≥12-week) were achieved in 20% of patients. Mild intraocular inflammation was reported in 1.7% of cases. Switching to faricimab in pre-treated nAMD led to sustained anatomical improvements and stabilization of BCVA, with a substantial reduction in RF compared to baseline. Our results suggest the potential benefits of this switch strategy based on real-world data.

12 December 2023 in European Journal of Ophthalmology
Verified
Journal Article
Closed access
APArianna Paris
Arianna Paris
BBBahram Bodaghi
Bahram Bodaghi
STSara Touhami
Sara Touhami
Purpose: To report a case of Fibroblast Growth Factor Receptor inhibitor (FGFRi) associated retinopathy in a patient treated with Erdafitinib. Case report: A patient with a history of non-muscle invasive urothelial carcinoma treated with Erdafitinib developed symptomatic unifocal bilateral serous retinal detachments (SRD) eight weeks after starting this new treatment. Six months after discontinuing the drug, the SRDs resolved and visual acuity recovered to baseline. However, hyper and hypo auto fluorescent lesions were still visible on fundus autofluorescence, suggesting a still ongoing retinal pigment epithelium (RPE) impairment. Conclusions: Cancer treatments using FGFRi are showing promising results but their ocular toxicity is not well reported nor fully understood. Oncologists should be aware of the potential risks associated with FGFRi and involve ophthalmologists for the follow-up of their patients. The toxicity of FGFRi seems to resolve after drug continuation, but a certain degree of infra clinical RPE impairment may persist. Longer term follow-ups are warranted to further understand the effects of FGFRi on the RPE.

3 July 2026 in Eye
Verified
Journal Article
Closed access
APArianna Paris
Arianna Paris
LWLaura Webster
Laura Webster
HEHaralabos Eleftheriadis
Haralabos Eleftheriadis
SMSamantha Mann
Samantha Mann